Conclusions
toxicity
The combination of pembrolizumab and cabozantinib treatment in patients with mRCC demonstrated encouraging preliminary efficacy that is comparable with other available CPI-TKI combinations with a manageable toxicity profile. Further prospective evaluation of pembrolizumab and cabozantinib is warranted, especially in the 2 L treatment setting and in patients with nccRCC.